These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 2185908)

  • 1. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).
    Ponto LL; Schoenwald RD
    Clin Pharmacokinet; 1990 May; 18(5):381-408. PubMed ID: 2185908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Torasemide. A review of its pharmacological properties and therapeutic potential.
    Friedel HA; Buckley MM
    Drugs; 1991 Jan; 41(1):81-103. PubMed ID: 1706990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.
    Ward A; Heel RC
    Drugs; 1984 Nov; 28(5):426-64. PubMed ID: 6391889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
    Sjöström P
    Scand J Urol Nephrol Suppl; 1988; 111():1-66. PubMed ID: 3201162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Clissold SP; Brogden RN
    Drugs; 1985 Jun; 29(6):489-530. PubMed ID: 3891305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of azosemide.
    Suh OK; Kim SH; Lee MG
    Biopharm Drug Dispos; 2003 Oct; 24(7):275-97. PubMed ID: 14520682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure.
    Chaturvedi PR; O'Donnell JP; Nicholas JM; Shoenthal DR; Waters DH; Gwilt PR
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):123-8. PubMed ID: 3557737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.
    Vree TB; van der Ven AJ
    J Pharm Pharmacol; 1999 Mar; 51(3):239-48. PubMed ID: 10344623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.
    Li T; Lee MG; Chiou WL
    J Pharmacokinet Biopharm; 1986 Oct; 14(5):495-509. PubMed ID: 3806372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.
    Alván G; Paintaud G; Eckernäs SA; Grahnén A
    Br J Clin Pharmacol; 1992 Jul; 34(1):47-52. PubMed ID: 1633067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diuretics].
    Schwartz J; Bloch R; Imbs JL; Spach MO
    Pathol Biol (Paris); 1986 Sep; 34(7):861-85. PubMed ID: 3537932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study of pharmacokinetics and effects on urinary secretion of electrolytes of furosemide and furosemide-amiloride in healthy subjects].
    Kantelip JP; Aiache JM; Beyssac E; Abella ML
    Therapie; 1991; 46(6):475-9. PubMed ID: 1819153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study.
    Silbert BI; Ho KM; Lipman J; Roberts JA; Corcoran TB; Morgan DJ; Pavey W; Mas E; Barden AE; Mori TA
    Crit Care Med; 2016 Oct; 44(10):e923-9. PubMed ID: 27183025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of furosemide delivery to its site of action.
    Sjöström PA; Kron BG; Odlind BG
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S38-41. PubMed ID: 7781204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diuretic effect and disposition of furosemide in cystic fibrosis.
    Prandota J; Smith IJ; Hilman BC; Wilson JT
    Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.
    Smith DE; Lin ET; Benet LZ
    Drug Metab Dispos; 1980; 8(5):337-42. PubMed ID: 6107232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling.
    Hammarlund MM; Odlind B; Paalzow LK
    J Pharmacol Exp Ther; 1985 May; 233(2):447-53. PubMed ID: 3999028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.